How the FASB’s new definition of a business impacts pharma/life sciences deals
By Shurjo Sen, PwC Deals Partner, Accounting Advisory In January 2017, the Financial Accounting Standards Board (FASB) issued new guidance …
Restructuring trends: What did we see in 2017 and what lies ahead for 2018?
By Steve Fleming, US Crisis and Restructuring Leader, PwC Deals In our recently released paper, Bankruptcy and Restructuring: 2017 in Review and …
Capturing deal value in Healthcare Services
By Angus Buchanan, Principal, PwC’s Deals Practice It’s no secret the healthcare market has undergone a wave of M&A activity over the past decade as service providers …
PwC’s Mid-year Deals Outlook: Slow start, but still active
Can we expect a dealmaking turnaround in 2016? Dealmaking significantly subsided in the first half of 2016 following a very active year. Equity market volatility, …
